Scientists Achieve Rapid Whole-Brain Imaging with Single Cell Resolution
|
By LabMedica International staff writers Posted on 15 Jun 2014 |

Image: Marmoset brain created using the CUBIC method (Photo courtesy of RIKEN).
An intensive effort has been made, particularly in the brain, to determine how neural activity is converted into consciousness and other complicated brain activities. A new high-throughput technology called CUBIC (clear, unobstructed brain imaging cocktails and computational analysis) appears to be a giant leap forward, as it offers unprecedented rapid whole-brain imaging at single cell resolution with a straightforward protocol to clear and make the brain sample transparent based on the use of amino-alcohols.
A key problem of systems biology is determining how phenomena at the cellular scale correlate with activity at the organism level. One example of the technologies that may provide better understanding of these phenomena is whole-brain imaging at single-cell resolution. This imaging typically involves preparing a highly transparent sample that minimizes light scattering and then imaging neurons tagged with fluorescent probes at different slices to generate a three-dimensional (3D) representation. However, limitations in current techniques prevent comprehensive study of the relationship. The project’s findings were published April 24, 2014, in the journal Cell.
In combination with light sheet fluorescence microscopy, CUBIC was evaluated for rapid imaging of a number of mammalian systems, such as mouse and primate, demonstrating its scalability for brains of different size. Moreover, it was used to acquire new spatial-temporal details of gene expression patterns in the hypothalamic circadian rhythm center. Moreover, by combining images captured from opposite directions, CUBIC enables whole brain imaging and direct comparison of brains in diverse environmental settings.
CUBIC tackles a number of obstacles compared with earlier strategies. One is the clearing and transparency protocol, which involves serially immersing fixed tissues into just two reagents for a comparatively short time. Second, CUBIC is compatible with many fluorescent probes because of low quenching, which allows for probes with longer wavelengths and lessens concern for scattering when whole brain imaging, while at the same time provides multicolor imaging. Lastly, it is highly reproducible and scalable. Whereas other approaches have achieved some of these abilities, CUBIC is the first to accomplish it all.
CUBIC provides data on earlier unattainable 3D gene expression profiles and neural networks at the systems level. Because of its rapid and high-throughput imaging, CUBIC offers an amazing opportunity to study localized effects of genomic editing. It also is expected to identify neural connections at the whole brain level. Last author Dr. Hiroki Ueda, from RIKEN (Saitama, Japan) is excited about further applications to even larger mammalian systems. “In the near future, we would like to apply CUBIC technology to whole-body imaging at single cell resolution.”
Related Links:
RIKEN
A key problem of systems biology is determining how phenomena at the cellular scale correlate with activity at the organism level. One example of the technologies that may provide better understanding of these phenomena is whole-brain imaging at single-cell resolution. This imaging typically involves preparing a highly transparent sample that minimizes light scattering and then imaging neurons tagged with fluorescent probes at different slices to generate a three-dimensional (3D) representation. However, limitations in current techniques prevent comprehensive study of the relationship. The project’s findings were published April 24, 2014, in the journal Cell.
In combination with light sheet fluorescence microscopy, CUBIC was evaluated for rapid imaging of a number of mammalian systems, such as mouse and primate, demonstrating its scalability for brains of different size. Moreover, it was used to acquire new spatial-temporal details of gene expression patterns in the hypothalamic circadian rhythm center. Moreover, by combining images captured from opposite directions, CUBIC enables whole brain imaging and direct comparison of brains in diverse environmental settings.
CUBIC tackles a number of obstacles compared with earlier strategies. One is the clearing and transparency protocol, which involves serially immersing fixed tissues into just two reagents for a comparatively short time. Second, CUBIC is compatible with many fluorescent probes because of low quenching, which allows for probes with longer wavelengths and lessens concern for scattering when whole brain imaging, while at the same time provides multicolor imaging. Lastly, it is highly reproducible and scalable. Whereas other approaches have achieved some of these abilities, CUBIC is the first to accomplish it all.
CUBIC provides data on earlier unattainable 3D gene expression profiles and neural networks at the systems level. Because of its rapid and high-throughput imaging, CUBIC offers an amazing opportunity to study localized effects of genomic editing. It also is expected to identify neural connections at the whole brain level. Last author Dr. Hiroki Ueda, from RIKEN (Saitama, Japan) is excited about further applications to even larger mammalian systems. “In the near future, we would like to apply CUBIC technology to whole-body imaging at single cell resolution.”
Related Links:
RIKEN
Latest BioResearch News
- Single-Cell Method Measures RNA and Proteins to Reveal Immune Responses
- Study Links Midlife Vitamin D to Lower Tau in Alzheimer's
- International Consensus Standardizes Tumor Microbiota Detection and Reporting
- Common Metablolic Enzyme Could Predict Response to Cancer Immunotherapy
- Newly Identfied Genetic Variants in MND Support Prognosis and Family Testing
- Innate Immunity Variants Associated With Earlier Breast Cancer in BRCA1 Carriers
- Genetic Cause Identified for Severe Infant Epilepsy
- Study Reveals Diagnostic and Therapeutic Target in Rare Pancreatic Tumors
- Researchers Identify Survival Pathway Undermining Targeted Cancer Drugs
- Large-Scale Study Maps DNA Damage Signatures Across Multiple Cancers
- Study Identifies Distinct Immune Signatures to Early Depression and Psychosis
- Genetic Mutation Behind Aggressive Adult Leukemia Offers Treatment Clues
- Disease Gene Discovery Advances Diagnosis of Rare Movement Disorders
- Genetic Discovery Could Improve Diagnosis of Drug-Resistant Epilepsy
- Genetic Discovery May Improve Diagnosis of Rare Dementia Subtype
- Mass Spectrometry Technique Detects Protein and Sugar Changes in Neurodegeneration
Channels
Clinical Chemistry
view channelNext Generation Automated Analyzers Increase Throughput for Clinical Chemistry and Electrolyte Testing
Clinical laboratories continue to face staffing shortages, limited space, and growing test volumes that pressure chemistry and electrolyte workflows. Maintaining rapid turnaround times increasingly depends... Read more
Blood Metabolite Test Detects Early Cognitive Decline
Timely identification of individuals at risk of dementia remains difficult because symptoms commonly appear only after significant neurodegeneration. Accessible screening tools that flag subtle cognitive... Read moreMolecular Diagnostics
view channel
Noninvasive Urine Test Predicts Recurrence After BCG in Bladder Cancer
Bladder cancer is among the most common malignancies in the United States and frequently recurs even when diagnosed at the non‑muscle invasive stage (NMIBC). After transurethral resection, many patients... Read more
Mesothelioma in Younger Adults Linked to Genetic Risk Factors
Mesothelioma is a rare malignancy of the pleura, historically linked to occupational asbestos exposure and most often diagnosed in older men. About 3,300 people are diagnosed each year in the United States,... Read moreHematology
view channel
New Platelet Function Assay Enables Monitoring of Antiplatelet Therapy
Monitoring response to antiplatelet therapy remains challenging for many clinical laboratories. Aggregation-based assays and cartridge systems often require specialized personnel, dedicated instruments,... Read more
Open Multi-Omics Platform Identifies Prognostic Subtypes in Blood Cancers
Blood cancers encompass diverse entities whose biology and clinical behavior are best understood through integrative analyses across large cohorts. However, multi‑omic datasets and outcomes information... Read moreImmunology
view channelCombined Screening Approach Identifies Early Leprosy Cases
Leprosy remains a significant public health concern, with more than 200,000 new cases reported globally each year and early disease often escaping routine laboratory detection. In its initial phase, bacterial... Read more
Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection
Active tuberculosis (TB) remains a leading cause of death and illness worldwide, yet distinguishing contagious disease from latent infection continues to challenge clinicians. Standard screening tools... Read more
FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas
Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
Bladder cancer remains a prevalent malignancy with variable responses to immune checkpoint inhibitors. Clinicians often observe elevated C-reactive protein and interleukin-6 in affected patients, yet the... Read moreMicrobiology
view channel
Cost-Effective Sampling and Sequencing Workflow Identifies ICU Infection Hotspots
Intensive care units face persistent threats from hospital-acquired infections, increasingly driven by drug-resistant bacteria. Rapidly pinpointing environmental reservoirs and transmission hotspots remains... Read more
New Bacterial Target Identified for Early Detection of Noma
Noma is a rapidly progressing orofacial infection that begins as gingivitis and can destroy oral and facial tissues, primarily affecting young children living in extreme poverty. Without treatment, it... Read morePathology
view channel
AI Tool Predicts Chemotherapy Response in Small Cell Lung Cancer
Small cell lung cancer often presents at an extensive stage and progresses rapidly, leaving little time to tailor first-line therapy. Clinicians currently lack biomarkers to guide which patients will benefit... Read more
Tumor-Specific Biomarker Predicts Neoadjuvant Immunotherapy Response in Gastric Cancer
Gastric cancer is the fifth most common malignancy and the fourth leading cause of cancer mortality worldwide, with China bearing nearly half of the global burden. Only a subset of patients benefit from... Read moreTechnology
view channel
Noninvasive Sputum Test Detects Early Lung Cancer
Early detection remains critical for improving outcomes in lung cancer, yet clinicians increasingly encounter indeterminate pulmonary nodules found incidentally or through screening, complicating decision-making.... Read more
New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
Children with T-cell acute lymphoblastic leukemia face an aggressive disease that remains difficult to treat. Although remission rates have improved, many survivors experience long-term effects from intensive... Read more
Breakthrough Mass Spectrometry Design Could Enable Ultra-Low Abundance Detection
Mass spectrometry is central to identifying and quantifying molecules in complex biological samples, but conventional instruments typically analyze ions sequentially, which can limit detection of rare species.... Read moreIndustry
view channel
GRAIL Partners with Epic to Integrate Multi-Cancer Test into EHR
GRAIL’s Galleri multi-cancer early detection (MCED) test is being integrated into Epic’s electronic health record (EHR) platform through Epic Aura. The collaboration is designed to let clinicians at interested... Read moreGlobal Partnership Aims to Streamline NGS Tumor Profiling in Oncology Trials
CellCarta and Pillar Biosciences announced a global, multi-year strategic partnership on April 2, 2026 to broaden access to operationally streamlined next-generation sequencing (NGS) tumor profiling for... Read more







